Skip to content
Study details
Enrolling now

Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD

NYU Langone Health
NCT IDNCT03667846ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

150

Study length

about 5.9 years

Ages

18–70

Locations

1 site in NY

What this study is about

Researchers are testing whether topiramate, a medication, helps people with both alcohol use disorder and post-traumatic stress disorder (PTSD). The trial will also investigate if certain genetic markers can predict how well someone responds to this treatment. It aims to understand how topiramate works in individuals with both conditions and identify factors that influence treatment success.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take Topiramate

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

topiramate

Drug routes

oral (Oral Tablet)

Body systems

Psychiatry / Mental Health